Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (151-160 of 213) with videos related to

Pageof 22
Sort By:
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Japanese Journal of Clinical Oncology|March 1, 2022
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysisNobuaki Matsubara, Kazuo Nishimura, Satoru Kawakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Plos One|April 11, 2015
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancerJean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects)Kenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer Old Problems and New Approaches. Part III. Prevention and TreatmentKenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pageof 22

Showing results (151-160 of 213) with videos related to

Sort By:
Pageof 22
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Japanese Journal of Clinical Oncology|March 1, 2022
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysisNobuaki Matsubara, Kazuo Nishimura, Satoru Kawakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Plos One|April 11, 2015
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancerJean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects)Kenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pathology Oncology Research : POR|January 1, 1996
Prostate Cancer Old Problems and New Approaches. Part III. Prevention and TreatmentKenneth V Honn, Amer Aref, Yong Q Chen, et al.
Pageof 22